<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769194</url>
  </required_header>
  <id_info>
    <org_study_id>VLA15-201</org_study_id>
    <nct_id>NCT03769194</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.</brief_title>
  <official_title>Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study conducted&#xD;
      in two study phases: a run-in phase and a main study phase. The study will investigate 3&#xD;
      doses of a multivalent OspA (Outer Surface Protein A)based Lyme vaccine (VLA15) in healthy&#xD;
      adults aged 18 to 65 years of age. Study participants will receive 3 immunizations of the&#xD;
      vaccine at a monthly interval. The study will assess the immune response as well as the&#xD;
      safety profile of the vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study.&#xD;
&#xD;
      In the Run-in phase, a total of 120 subjects aged 18 to 40 years will be randomized 1:1:1:1&#xD;
      to receive one of three VLA15 doses (VLA15 low dose, VLA15 medium dose, VLA15 high dose) or&#xD;
      Placebo (30 subjects per treatment group) as intramuscular vaccinations on Days 1, 29 and 57.&#xD;
      Dosing will be adjusted by injection volume.&#xD;
&#xD;
      In the Main Study phase, a total of 450 subjects aged 18 to 65 years will be randomized 2:2:1&#xD;
      to receive one of two VLA15 doses that are selected from the Run-in Phase for further&#xD;
      investigation (180 subjects each) or placebo (90 subjects), as intramuscular vaccinations on&#xD;
      Days 1, 29 and 57. Subjects will be enrolled in two age groups (18-49 years and 50-65 years)&#xD;
      in a ratio of approx. 2:1.&#xD;
&#xD;
      In both study phases, target is to enroll approx. 10 % or more of subjects that are baseline&#xD;
      seropositive for Borrelia burgdorferi sensu latu (Bb s.l.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Actual">October 2, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6</measure>
    <time_frame>up to Day 85 / Month 3</time_frame>
    <description>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype ST1 to ST6, determined by ELISA at Day 85</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCRs (Seroconversion Rate, Defined as Four-fold Increase in IgG (Immunoglobulin G) Titer Compared to Baseline) for Each OspA (Outer Surface Protein A) Serotype Specific IgG (Immunoglobulin G) (ST1 to ST6),</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>SCRs (Seroconversion Rate, defined as four-fold increase in IgG (Immunoglobulin G) titer compared to baseline) for each OspA serotype specific IgG (Immunoglobulin G) (ST1 to ST6), determined by ELISA,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>GMFR (Geometric Mean of the fold rise as compared to baseline) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs (Geometric Mean Titers), SCRs (Seroconversion Rate) and GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6),</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>GMTs (Geometric Mean Titers), SCRs (Seroconversion Rate) and GMFRs (Geometric Mean of the fold rise as compared to baseline) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA, stratified by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAEs (Serious Adverse Events)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of SAEs (Serious Adverse Events) during the entire study;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related SAEs (Serious Adverse Events)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of related SAEs (Serious Adverse Events) during the entire study;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AESIs (Adverse Events of Special Interest)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of AESIs (Adverse Events of Special Interest) during the entire study;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related AESIs (Adverse Events of Special Interest)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of related AESIs (Adverse Events of Special Interest) during the entire study;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited AEs (Adverse Events)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Unsolicited AEs (Adverse Events)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of related unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Local and Solicited Systemic AEs (Adverse Events)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of solicited local and solicited systemic AEs (Adverse Events) within 7 days after each and after any vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), Solicited and Unsolicited AEs (Adverse Events)</measure>
    <time_frame>up to Day 365 / Month 12</time_frame>
    <description>Frequency of SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), solicited and unsolicited AEs (Adverse Events) during the entire study stratified by age group.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">572</enrollment>
  <condition>Lyme Borreliosis</condition>
  <arm_group>
    <arm_group_label>VLA15 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLA15 low dose with Alum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLA15 medium dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLA15 medium dose with Alum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLA15 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLA15 high dose with Alum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VLA15</intervention_name>
    <description>a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate</description>
    <arm_group_label>VLA15 high dose</arm_group_label>
    <arm_group_label>VLA15 low dose</arm_group_label>
    <arm_group_label>VLA15 medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: PBS (Phosphate Buffered Saline)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Run-in phase:&#xD;
&#xD;
        1. Subject is aged 18 to 40 years at the day of screening (Visit 0);&#xD;
&#xD;
        Main Study phase:&#xD;
&#xD;
          1. Subject is aged18 to 65 years at the day of screening (Visit 0);&#xD;
&#xD;
             Run-in phase and Main Study phase:&#xD;
&#xD;
          2. Subject is of good general health, including subjects with pharmacologically&#xD;
             controlled chronic conditions;&#xD;
&#xD;
          3. Subject has an understanding of the study and its procedures, agrees to its&#xD;
             provisions, and gives written informed consent prior to any study-related procedures;&#xD;
&#xD;
          4. If subject is of childbearing potential:&#xD;
&#xD;
               1. Subject has a negative serum pregnancy test at screening (Visit 0);&#xD;
&#xD;
               2. Subject agrees to employ adequate birth control measures for the duration of the&#xD;
                  study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a chronic illness related to Lyme borreliosis (LB), an active symptomatic&#xD;
             LB (Lyme borreliosis) as suspected or diagnosed by a physician, or received treatment&#xD;
             for LB (Lyme borreliosis) within the last 3 months prior to Visit 0;&#xD;
&#xD;
          2. Subject received previous vaccination against Lyme borreliosis (LB).;&#xD;
&#xD;
          3. Subject had a tick bite within 4 weeks prior to Visit 1;&#xD;
&#xD;
          4. Subject has a medical history of or currently has a clinically relevant disease&#xD;
             (cardiovascular, respiratory, neurologic, psychiatric conditions) which poses a risk&#xD;
             for participation in the study, based on investigators judgement, such as individuals&#xD;
             with poorly controlled or unstable disease, ongoing suspected or active inflammation,&#xD;
             or poor compliance with pharmacologic treatment. Subjects with pharmacologically&#xD;
             controlled conditions like osteoarthritis, depression, or asthma are eligible;&#xD;
&#xD;
          5. Subject has a medical history of or currently has a neuroinflammatory or autoimmune&#xD;
             disease, including Guillain Barré Syndrome;&#xD;
&#xD;
          6. Subject has a known thrombocytopenia, bleeding disorder, or received anticoagulants in&#xD;
             the 3 weeks prior to first vaccination or until Day 57 (Visit 3), contraindicating&#xD;
             intramuscular vaccination as judged by the investigator;&#xD;
&#xD;
          7. Subject has received an active or passive immunization within 28 days before first&#xD;
             vaccination at Visit 1 and until Day 85; except for influenza (seasonal or pandemic)&#xD;
             and pneumococcal vaccines which may be administered outside a 7-days interval before&#xD;
             or after any trial vaccination;&#xD;
&#xD;
          8. Subject has received any other non-registered medicinal product in another clinical&#xD;
             trial within 28 days prior to VLA15 vaccination at Visit 1 (Day 1) and throughout the&#xD;
             entire study period or has received a registered medicinal product in another clinical&#xD;
             trial within 28 days prior to VLA15 vaccination at Visit 1 (Day 1) and up to Day 85;&#xD;
&#xD;
          9. Subject has a known or suspected defect of the immune system that would prevent an&#xD;
             immune response to the vaccine, such as subjects with congenital or acquired&#xD;
             immunodeficiency, including infection with human immunodeficiency virus (HIV), status&#xD;
             post organ transplantation or immuno-suppressive therapy within 30 days prior to Visit&#xD;
             1. Immuno-suppressive therapy is defined as administration of chronic (longer than 14&#xD;
             days) prednisone or equivalent 0.05 mg per kg/ per day. Topical and inhaled steroids&#xD;
             are allowed;&#xD;
&#xD;
         10. Subject has a history of anaphylaxis or severe allergic reactions or a known&#xD;
             hypersensitivity or allergic reactions to one of the components of the vaccine;&#xD;
&#xD;
         11. Subject had any malignancy in the past 5 years. If treatment for cancer was&#xD;
             successfully completed more than 5 years ago and the malignancy is considered to be&#xD;
             cured, the subject may be enrolled;&#xD;
&#xD;
         12. Subject had acute febrile infections within 10 days prior to first vaccination;&#xD;
&#xD;
         13. Subject is pregnant (positive serum pregnancy test at screening), has plans to become&#xD;
             pregnant during the course of the study or is lactating at the time of enrollment.&#xD;
             Women of childbearing potential that are unwilling or unable to employ an adequate&#xD;
             birth control measure for the duration of the study.&#xD;
&#xD;
         14. Subject has donated blood or blood-derived products (plasma) within 30 days or&#xD;
             received blood or blood-derived products (plasma) within 90 days prior to first&#xD;
             vaccination in this study or plans to donate or use blood or blood products during the&#xD;
             course of the study;&#xD;
&#xD;
         15. Subject has any condition that, in the opinion of the investigator, may compromise the&#xD;
             subject's well-being, might interfere with evaluation of study endpoints, or would&#xD;
             limit the subject's ability to complete the study;&#xD;
&#xD;
         16. Subject is committed to an institution (by virtue of an order issued either by the&#xD;
             judicial or the administrative authorities);&#xD;
&#xD;
         17. Subject is in a dependent relationship with the sponsor, an investigator or other&#xD;
             study team member, or the study center. Dependent relationships include close&#xD;
             relatives and household members (i.e. children, partner/spouse, siblings, parents) as&#xD;
             well as employees of the investigator or study center personnel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Consulting, LLC</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stamford Therapeutics Consortium</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cevac Center for vaccinology</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berliner Centrum für Reise- und Tropenmedizin (BCRT)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <results_first_submitted>May 5, 2021</results_first_submitted>
  <results_first_submitted_qc>June 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VLA15, Lyme Borreliosis, Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Borrelia Infections</mesh_term>
    <mesh_term>Lyme Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03769194/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03769194/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VLA15 Low Dose</title>
          <description>VLA15 low dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="P2">
          <title>VLA15 Medium Dose</title>
          <description>VLA15 medium dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="P3">
          <title>VLA15 High Dose</title>
          <description>VLA15 high dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: Placebo: PBS (Phosphate Buffered Saline)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="214"/>
                <participants group_id="P3" count="205"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="204"/>
                <participants group_id="P3" count="201"/>
                <participants group_id="P4" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VLA15 Low Dose</title>
          <description>VLA15 low dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="B2">
          <title>VLA15 Medium Dose</title>
          <description>VLA15 medium dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="B3">
          <title>VLA15 High Dose</title>
          <description>VLA15 high dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: Placebo: PBS (Phosphate Buffered Saline)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="205"/>
            <count group_id="B4" value="124"/>
            <count group_id="B5" value="572"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="6.13"/>
                    <measurement group_id="B2" value="41.7" spread="13.26"/>
                    <measurement group_id="B3" value="41.6" spread="12.56"/>
                    <measurement group_id="B4" value="40.7" spread="12.80"/>
                    <measurement group_id="B5" value="40.8" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6</title>
        <description>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype ST1 to ST6, determined by ELISA at Day 85</description>
        <time_frame>up to Day 85 / Month 3</time_frame>
        <population>Overall Number of Participants Analyzed Per Protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>VLA15 Low Dose</title>
            <description>VLA15 low dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
          </group>
          <group group_id="O2">
            <title>VLA15 Medium Dose</title>
            <description>VLA15 medium dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
          </group>
          <group group_id="O3">
            <title>VLA15 High Dose</title>
            <description>VLA15 high dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: Placebo: PBS (Phosphate Buffered Saline)</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6</title>
          <description>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype ST1 to ST6, determined by ELISA at Day 85</description>
          <population>Overall Number of Participants Analyzed Per Protocol population</population>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ST1 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="46.4" upper_limit="119.0"/>
                    <measurement group_id="O2" value="101.1" lower_limit="86.3" upper_limit="118.4"/>
                    <measurement group_id="O3" value="115.8" lower_limit="98.8" upper_limit="135.7"/>
                    <measurement group_id="O4" value="21.7" lower_limit="20.0" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST2 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.9" lower_limit="124.8" upper_limit="262.3"/>
                    <measurement group_id="O2" value="276.9" lower_limit="244.8" upper_limit="313.1"/>
                    <measurement group_id="O3" value="303.7" lower_limit="266.5" upper_limit="346.1"/>
                    <measurement group_id="O4" value="21.1" lower_limit="20.0" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST3 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.4" lower_limit="194.8" upper_limit="367.1"/>
                    <measurement group_id="O2" value="282.2" lower_limit="247.5" upper_limit="321.8"/>
                    <measurement group_id="O3" value="308.6" lower_limit="266.8" upper_limit="356.8"/>
                    <measurement group_id="O4" value="20.8" lower_limit="19.8" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST4 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.0" lower_limit="76.6" upper_limit="178.7"/>
                    <measurement group_id="O2" value="169.7" lower_limit="149.4" upper_limit="192.8"/>
                    <measurement group_id="O3" value="190.7" lower_limit="165.9" upper_limit="219.2"/>
                    <measurement group_id="O4" value="21.8" lower_limit="20.4" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST5 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" lower_limit="78.3" upper_limit="178.9"/>
                    <measurement group_id="O2" value="174.6" lower_limit="152.9" upper_limit="199.4"/>
                    <measurement group_id="O3" value="199.6" lower_limit="172.5" upper_limit="230.9"/>
                    <measurement group_id="O4" value="21.4" lower_limit="20.2" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST6 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.6" lower_limit="76.5" upper_limit="174.7"/>
                    <measurement group_id="O2" value="182.6" lower_limit="160.9" upper_limit="207.2"/>
                    <measurement group_id="O3" value="208.7" lower_limit="181.8" upper_limit="239.6"/>
                    <measurement group_id="O4" value="21.8" lower_limit="20.3" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6)</title>
        <description>GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA,</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCRs (Seroconversion Rate, Defined as Four-fold Increase in IgG (Immunoglobulin G) Titer Compared to Baseline) for Each OspA (Outer Surface Protein A) Serotype Specific IgG (Immunoglobulin G) (ST1 to ST6),</title>
        <description>SCRs (Seroconversion Rate, defined as four-fold increase in IgG (Immunoglobulin G) titer compared to baseline) for each OspA serotype specific IgG (Immunoglobulin G) (ST1 to ST6), determined by ELISA,</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6)</title>
        <description>GMFR (Geometric Mean of the fold rise as compared to baseline) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA,</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs (Geometric Mean Titers), SCRs (Seroconversion Rate) and GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6),</title>
        <description>GMTs (Geometric Mean Titers), SCRs (Seroconversion Rate) and GMFRs (Geometric Mean of the fold rise as compared to baseline) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA, stratified by age group.</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAEs (Serious Adverse Events)</title>
        <description>Frequency of SAEs (Serious Adverse Events) during the entire study;</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related SAEs (Serious Adverse Events)</title>
        <description>Frequency of related SAEs (Serious Adverse Events) during the entire study;</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AESIs (Adverse Events of Special Interest)</title>
        <description>Frequency of AESIs (Adverse Events of Special Interest) during the entire study;</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related AESIs (Adverse Events of Special Interest)</title>
        <description>Frequency of related AESIs (Adverse Events of Special Interest) during the entire study;</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited AEs (Adverse Events)</title>
        <description>Frequency of unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters);</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Unsolicited AEs (Adverse Events)</title>
        <description>Frequency of related unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters);</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited Local and Solicited Systemic AEs (Adverse Events)</title>
        <description>Frequency of solicited local and solicited systemic AEs (Adverse Events) within 7 days after each and after any vaccination.</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), Solicited and Unsolicited AEs (Adverse Events)</title>
        <description>Frequency of SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), solicited and unsolicited AEs (Adverse Events) during the entire study stratified by age group.</description>
        <time_frame>up to Day 365 / Month 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to Day 85</time_frame>
      <desc>Solicited AEs comprised injection site reactions (pain, itching, tenderness, induration (hardening), swelling, erythema (redness)) or systemic reactions (headache, muscle pain, fever (oral), flu-like symptoms, nausea, vomiting, rash, excessive fatigue). Solicited AEs are collected by systematic assessment through subject diaries and unsolicited AEs are collected through non-systematic assessment. Unsolicited Adverse Events including SAEs are reported up to Day 85 below.</desc>
      <group_list>
        <group group_id="E1">
          <title>VLA15 Low Dose</title>
          <description>VLA15 low dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="E2">
          <title>VLA15 Medium Dose</title>
          <description>VLA15 medium dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="E3">
          <title>VLA15 High Dose</title>
          <description>VLA15 high dose with Alum.&#xD;
VLA15: a multivalent Outer surface protein A (OspA) based vaccine candidate</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: Placebo: PBS (Phosphate Buffered Saline)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Herpes oster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="202" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="200" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>includes systematic and non-systematic assessments</description>
                <counts group_id="E1" events="111" subjects_affected="26" subjects_at_risk="29"/>
                <counts group_id="E2" events="923" subjects_affected="198" subjects_at_risk="214"/>
                <counts group_id="E3" events="940" subjects_affected="196" subjects_at_risk="205"/>
                <counts group_id="E4" events="57" subjects_affected="30" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>includes systematic and non-systematic assessments</description>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" events="108" subjects_affected="65" subjects_at_risk="214"/>
                <counts group_id="E3" events="129" subjects_affected="80" subjects_at_risk="205"/>
                <counts group_id="E4" events="40" subjects_affected="29" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" events="116" subjects_affected="68" subjects_at_risk="214"/>
                <counts group_id="E3" events="123" subjects_affected="72" subjects_at_risk="205"/>
                <counts group_id="E4" events="18" subjects_affected="12" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="108" subjects_affected="64" subjects_at_risk="214"/>
                <counts group_id="E3" events="108" subjects_affected="65" subjects_at_risk="205"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="84" subjects_affected="57" subjects_at_risk="214"/>
                <counts group_id="E3" events="104" subjects_affected="68" subjects_at_risk="205"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <description>includes systematic and non-systematic assessments</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="36" subjects_affected="25" subjects_at_risk="214"/>
                <counts group_id="E3" events="38" subjects_affected="34" subjects_at_risk="205"/>
                <counts group_id="E4" events="22" subjects_affected="17" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="31" subjects_affected="23" subjects_at_risk="214"/>
                <counts group_id="E3" events="36" subjects_affected="32" subjects_at_risk="205"/>
                <counts group_id="E4" events="15" subjects_affected="11" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>includes systematic and non-systematic assessments</description>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="29"/>
                <counts group_id="E2" events="173" subjects_affected="106" subjects_at_risk="214"/>
                <counts group_id="E3" events="156" subjects_affected="97" subjects_at_risk="205"/>
                <counts group_id="E4" events="29" subjects_affected="21" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>includes systematic and non-systematic assessments</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="57" subjects_affected="36" subjects_at_risk="214"/>
                <counts group_id="E3" events="49" subjects_affected="37" subjects_at_risk="205"/>
                <counts group_id="E4" events="19" subjects_affected="12" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>includes systematic and non-systematic assessments</description>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" events="110" subjects_affected="71" subjects_at_risk="214"/>
                <counts group_id="E3" events="128" subjects_affected="83" subjects_at_risk="205"/>
                <counts group_id="E4" events="41" subjects_affected="30" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director Clinical Strategy</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>+43120620 ext 0</phone>
      <email>office@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

